Piper Sandler lowered the firm’s price target on Cytek Biosciences to $8.50 from $10 following quarterly results. The firm keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences backs FY24 revenue view $203M-$213M, consensus $207.89M
- Cytek Biosciences reports Q1 EPS (5c), consensus (4c)
- Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
- Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
- Cytek Biosciences Announces CFO Transition and New Appointment
